Placenta Stem Cells

Phase 1

WWake Forest University Health Sciences

Placenta Stem Cells is one of 4 therapeutic programs targeting Diabetic Foot Ulcer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic Foot UlcerNot yet recruiting

Diabetic Foot UlcerPhase 1

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Diabetic Foot Ulcer

#DrugCompanyPhaseTrials

L-Carnitine

IIperboreal Pharma Srl

Phase 2

1 2

BB-101

BBlue Blood Biotech Corp.

Phase 2

1 3

Propolis

IIndonesia University

Preclinical

1 4

Placenta Stem Cells

WWake Forest University Health Sciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Diabetic Foot Ulcer

NCT07686094

Clinical

Trials by Indication[1]

Diabetic Foot Ulcer1 trial

Phase 1 Safety Trial of Placental Stem Cells (PLSC) to Accelerate the Healing of Diabetic Foot Ulcers

Not yet recruiting·WWake Forest University Health Sciences·Phase 1·NCT07686094·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placenta Stem Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placenta Stem Cells. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: WWake Forest University Health Sciences

Placenta Stem Cells

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Diabetic Foot Ulcer1 trial

References

Drug Info

Quick Facts

Related News